NSCLC

Non-small-cell lung carcinoma is any type of epithelial lung cancer other than small-cell lung carcinoma. NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively and postoperatively.

Read more in the app

Investigational immunotherapy nearly doubles overall survival compared with docetaxel in advanced squamous NSCLC

Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastases

Study identifies distinct outcomes and genomic features in NSCLC with class II and III BRAF alterations

Phase 3 DESTINY-Lung04 trial shows first-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant NSCLC

Eight-year ADAURA update shows sustained overall survival benefit with adjuvant osimertinib in resected EGFR-mutated NSCLC

Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR exon 20 insertion-positive NSCLC

Zidesamtinib demonstrates 94% response rate in TKI-naive patients with advanced ROS1-positive NSCLC

In the PAPILLON study, first-line amivantamab-chemotherapy demonstrates the longest overall survival reported for EGFR exon 20 insertion-positive advanced NSCLC

Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC

Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC

Adjuvant immunotherapy shows no survival benefit for NSCLC patients achieving pCR after neoadjuvant treatment

Epithelial–mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC) - EurekAlert!

Efficacy and safety of immune checkpoint inhibitors in EGFR-mutant NSCLC patients with EGFR-TKI resistance: an updated systematic review and meta-analysis - EurekAlert!

New horizons in NSCLC targeted therapy: advancements and challenges - EurekAlert!

Novel immunotherapy strategy shows promising long-term survival in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors - EurekAlert!

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors - EurekAlert!

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy - EurekAlert!

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study - EurekAlert!